Accès à distance ? S'identifier sur le proxy UCLouvain
Improvement in DAS28 response through one-year of golimumab treatment in patients with active RA despite treatment with methotrexate: A phase II, randomized, double blind, placebo controlled, dose ranging trial
Primary tabs
| Document type | Communication à un colloque (Conference Paper) – Abstract, Présentation orale avec comité de sélection |
|---|---|
| Publication date | 2007 |
| Language | Anglais |
| Conference | "Annual European Congress of Rheumatology (EULAR 2007)", Barcelona (Spain) (Jun 13-16, 2007) |
| Journal information | "Annals of the Rheumatic Diseases" - Vol. 66, p. 175-176 (2007) |
| Peer reviewed | yes |
| issn | 0003-4967 |
| e-issn | 1468-2060 |
| Publisher | B M J Publishing Group (London) |
| Affiliations |
UCL
- Cliniques universitaires Saint-Luc UCL - MD/MINT - Département de médecine interne |
| Links |
| Bibliographic reference | Kay, J. ; Durez, Patrick ; Matteson, E. L. ; Dasgupta, B. ; Nash, P. ; et. al. Improvement in DAS28 response through one-year of golimumab treatment in patients with active RA despite treatment with methotrexate: A phase II, randomized, double blind, placebo controlled, dose ranging trial.Annual European Congress of Rheumatology (EULAR 2007) (Barcelona (Spain), Jun 13-16, 2007). In: Annals of the Rheumatic Diseases, Vol. 66, p. 175-176 (2007) |
|---|---|
| Permanent URL | http://hdl.handle.net/2078.1/59327 |